Efficacy of Primary Systemic Chemotherapy Regimen Containing Anthracyclines with/without Taxanes in Comparison to CMF in Women with Early Breast Cancer

References

• Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and rec-ommendations. J Clin Oncol. 2003; 21 (13): 2600–8.
   Google Scholar
• Kaufmann M, Hotobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940.
   Google Scholar
• Fisher B, Brown A, Mamounas E et al. Effect of preop-erative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15 (7): 2483-93.
   PubMed Web of Science ®Google Scholar
• Gianni L, Base1ga J, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative chemotherapy. Clin Cancer Res. 2005; 11 (24 Pt 1): 8715-21.
   PubMed Web of Science ®Google Scholar
• Mauri D, Pavlidis N, Joannidis JP. Neoadjuvant versus adjuvant ystemic treatment in breast cancer : a meta-analysis. J Natl Cancer Inst 2005: 97:188.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimetres or more. J Natl Cancer Inst. 1990; 82 (19): 1539–45.
   PubMed Web of Science ®Google Scholar
• Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol. 1995; 13 (3): 537–40.
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;(30):96-102.
   Google Scholar
• Thomas E, Holmes FA, Smith TL et al. The use of alter-nate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004; 22:2294.
   Google Scholar
• Hennessy BT, Hortobagyi GN, Rouzier R et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following prima-ry chemotherapy. J Clin Oncol 2005; 23: 9304.
   Google Scholar
• Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary cheomotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037
   Google Scholar
• Cocconi G, Di Blasio B, Boni C et al. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses trans-lated into long-term outcomes. Ann Oncol. 2005; 16 (9): 1469-76.
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352 (9132): 930-42.
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cyto-toxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992; 339 (8785): 71–85.
   PubMedGoogle Scholar
• Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19 (3): 278–85.
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Burris HA 3rd, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracene-dione-resistant breast cancer. J Clin Oncol. 1995; 13 (12): 2879–85.
   PubMedGoogle Scholar
• Clemons M, Leahy M, Valle J, Jayson G, Ranson M, Howell A. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur J Cancer. 1997; 33 (13): 2183–93.
   PubMed Web of Science ®Google Scholar
• Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13 (12): 2886–94.
   Google Scholar
• Nabholtz JM, Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: prelimi-nary results. Semin Oncol. 1998; 25 (6 Suppl 13): 4-9.
   Google Scholar
• Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006; 24 (20): 3245–51.
   PubMed Web of Science ®Google Scholar
• Husband JE, Schwartz LH, Spencer J et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004; 90:2256.
   Google Scholar
• Gehan EA, Tef ft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000; 92:179.
   Google Scholar
• Trudeau M, Sinclair SE, Clemons M. Neoadjuvant tax-anes in the treatment of non-metastatic breast cancer: a sys-tematic review. Cancer Treat Rev 2005; 31: 283–302.
   PubMed Web of Science ®Google Scholar
• Ring AE, Ellis PA. Taxanes in the treatment of early breast cancer. Cancer Treat Rev 2005; 31: 618–627.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPAR-DUO study of the German Breast Group. J Clin Oncol. 2005; 23 (12): 2676-85.
   PubMed Web of Science ®Google Scholar
• smith jc, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20 (6): 1456-1466.
   Google Scholar
• Hutcheon AW, Heys SD, Sarkar TK et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Presented at the 26th annual San Antonio Breast Cancer Symposiom, San Antonio, TX, December 2003 (abstract 11).
   Google Scholar
• French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol. 2000; 18 (17): 3115-24.
   Google Scholar
• Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from esca-lating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21 (6): 976-83.
   PubMed Web of Science ®Google Scholar
• Mamounas EP. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Williston Park). 1997; 11(6 Suppl 6):37-40.
   Google Scholar
• Bear HD, Anderson S, Smith RE et al. Sequential pre-operative or postoperative docetaxel added to preoperative doxorubicin plus cyclophsphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019.
   Google Scholar
• Steger GG, Kubista E, Hausmaninger H, et al. 6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings Vol 22, No 14S (July 15 Supplement), 2004: 553. Fitzal F, Gnant M. Breast conservation: evolution of sur-gical strategies. Breast J. 2006; Suppl 2: S165-73.
   Google Scholar